Tags

Type your tag names separated by a space and hit enter

Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden.
Scand J Infect Dis. 2008; 40(9):721-9.SJ

Abstract

The 7-valent pneumococcal conjugate vaccine (PCV-7) has proved to be highly effective against invasive pneumococcal disease and has also provided some protection against all-cause pneumonia and acute otitis media. The objective of this study was to evaluate the projected health benefits, costs and cost-effectiveness of vaccination with the 7-valent conjugated pneumococcal vaccine compared with no vaccination, in all infants in Sweden, taking herd immunity into account. A Markov model was used and a hypothetical birth cohort was simulated for a lifelong perspective. The results show that vaccination of 1 cohort could potentially prevent 9 cases of pneumococcal meningitis, 22 cases of pneumococcal septicaemia, 509 cases of hospitalized pneumonia, 7812 cases of acute otitis media, and 2.7 fatalities, among children 0-4 y of age and 6 episodes of pneumococcal meningitis and 167 cases of pneumococcal septicaemia among adults. The incremental cost per QALY and LY gained was estimated to Euro 29,200 and Euro 51,400, respectively. When herd immunity was accounted for, the cost per QALYand LY gained was estimated to Euro 5500 and Euro 6600, respectively. Thus, the health benefits of a national vaccination programmeme can be achieved within a 'moderate' or 'low' cost per QALY gained.

Authors+Show Affiliations

Swedish Institute for Health Economics, Lund, Sweden. ab@ihe.seNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18712627

Citation

Bergman, Annika, et al. "Cost-effectiveness Analysis of a Universal Vaccination Programme With the 7-valent Pneumococcal Conjugate Vaccine (PCV-7) in Sweden." Scandinavian Journal of Infectious Diseases, vol. 40, no. 9, 2008, pp. 721-9.
Bergman A, Hjelmgren J, Ortqvist A, et al. Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden. Scand J Infect Dis. 2008;40(9):721-9.
Bergman, A., Hjelmgren, J., Ortqvist, A., Wisløff, T., Kristiansen, I. S., Högberg, L. D., Persson, K. M., & Persson, U. (2008). Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden. Scandinavian Journal of Infectious Diseases, 40(9), 721-9. https://doi.org/10.1080/00365540802014872
Bergman A, et al. Cost-effectiveness Analysis of a Universal Vaccination Programme With the 7-valent Pneumococcal Conjugate Vaccine (PCV-7) in Sweden. Scand J Infect Dis. 2008;40(9):721-9. PubMed PMID: 18712627.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden. AU - Bergman,Annika, AU - Hjelmgren,Jonas, AU - Ortqvist,Ake, AU - Wisløff,Torbjørn, AU - Kristiansen,Ivar Sønbø, AU - Högberg,Liselotte Diaz, AU - Persson,Kristina M S, AU - Persson,Ulf, PY - 2008/8/21/pubmed PY - 2009/1/6/medline PY - 2008/8/21/entrez SP - 721 EP - 9 JF - Scandinavian journal of infectious diseases JO - Scand J Infect Dis VL - 40 IS - 9 N2 - The 7-valent pneumococcal conjugate vaccine (PCV-7) has proved to be highly effective against invasive pneumococcal disease and has also provided some protection against all-cause pneumonia and acute otitis media. The objective of this study was to evaluate the projected health benefits, costs and cost-effectiveness of vaccination with the 7-valent conjugated pneumococcal vaccine compared with no vaccination, in all infants in Sweden, taking herd immunity into account. A Markov model was used and a hypothetical birth cohort was simulated for a lifelong perspective. The results show that vaccination of 1 cohort could potentially prevent 9 cases of pneumococcal meningitis, 22 cases of pneumococcal septicaemia, 509 cases of hospitalized pneumonia, 7812 cases of acute otitis media, and 2.7 fatalities, among children 0-4 y of age and 6 episodes of pneumococcal meningitis and 167 cases of pneumococcal septicaemia among adults. The incremental cost per QALY and LY gained was estimated to Euro 29,200 and Euro 51,400, respectively. When herd immunity was accounted for, the cost per QALYand LY gained was estimated to Euro 5500 and Euro 6600, respectively. Thus, the health benefits of a national vaccination programmeme can be achieved within a 'moderate' or 'low' cost per QALY gained. SN - 0036-5548 UR - https://www.unboundmedicine.com/medline/citation/18712627/Cost_effectiveness_analysis_of_a_universal_vaccination_programme_with_the_7_valent_pneumococcal_conjugate_vaccine__PCV_7__in_Sweden_ L2 - https://www.tandfonline.com/doi/full/10.1080/00365540802014872 DB - PRIME DP - Unbound Medicine ER -